Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection

doi:10.3877/cma.j.issn.1674-6902.2024.04.007

Abstract

Abstract:

Objective

To analyze the prognostic significance of long non-coding RNA small nucleolar RNA host gene 17 (SNHG17) expression in non-small cell lung cancer (NSCLC) resection.

Methods

A total of 87 patients with NSCLC undergoing radical surgery in our hospital from January 2020 to June 2022 were selected as the subjects. After the operation, recurrence-free survival (RFS) and overall survival (OS) were recorded. The expression level of SNHG17 was detected by real-time fluorescence quantitative PCR.

Results

The expression of SNHG17 in NSCLC tissues (1.85±0.61) was higher than that in adjacent normal tissues (1.03±0.36)(P<0.05). TNM stage Ⅰ SNHG17 expression (1.52±0.25), stage Ⅱ (1.83±0.66)(t=2.283, P<0.05), stage Ⅲ SNHG17 expression (2.28±0.58)(t=6.058, P<0.05). The expression of SNHG17 in stage Ⅲ was higher than that in stage Ⅱ(P<0.05). There were 43 cases with high SNHG17 expression (≥1.72) and 44 cases with low SNHG17 expression (<1.72). The expression of SNHG17 in NSCLC tissues was correlated with TNM stage (P<0.05). During the follow-up period, 43 cases (49.43%) relapsed and 33 cases (37.93%) died. Compared with 33 cases (75.00%) with low expression of SNHG17, 11 cases (25.58%) with high expression of SNHG17 had no recurrence, and the median RFS time of low expression of SNHG17 was 4.30 years longer than that of high expression of SNHG17 2.40 years(P<0.05). The survival rate of 35 patients (79.55%) with low expression of SNHG17 was higher than that of 19 patients(44.19%) with high expression. The median OS time of low expression of SNHG17 was 5.11 years longer than that of high expression 4.28 years)(P<0.05). COX regression analysis showed that high expression of SNHG17 was a predictor of recurrence and death after NSCLC resection (P<0.05).

Conclusion

SNHG17 is highly expressed in NSCLC tissues, and high expression is closely related to the risk of recurrence and death of NSCLC. SNHG17 is a promising biomarker for predicting the prognosis of surgically resected NSCLC.

Key words: Non-small cell lung cancer, Small nucleolar RNA host gene 17, Surgical excision, Prognosis

Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2024.04.007

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2024/V17/I04/543

Figures/Tables 2

References 28

1	Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nature Reviews Clinical Oncology, 2023, 20(9): 624-639.
2	Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
3	Montagne F, Guisier F, Venissac N, et al. The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art[J]. Cancers, 2021, 13(15): 3711-3733.
4	Li N, Wang BX, Li J, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to ⅢA non-small cell lung cancer[J]. Cancer, 2022, 128(4): 708-718.
5	Cao Z, Oyang L, Luo X, et al. The roles of long non-coding RNAs in lung cancer[J]. Journal of cancer, 2022, 13(1): 174-183.
6	赵　效，张冰海，李晓霞，等. 长链非编码RNA与非小细胞肺癌相关性的研究进展[J]. 国际生物医学工程杂志，2021, 44(1): 60-64.
7	Ghahramani Almanghadim H, Ghorbian S, Khademi NS, et al. New insights into the importance of long non-coding RNAs in lung cancer: future clinical approaches[J]. DNA and Cell Biology, 2021, 40(12): 1476-1494.
8	Entezari M, Ghanbarirad M, Taheriazam A, et al. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling[J]. Biomed Pharmacother, 2022, 150: 112963.
9	李　渊，王欣鑫，陈世勇，等. 小核仁RNA宿主基因17在癌症进展中的作用研究进展[J]. 解放军医学杂志，2022, 47(9): 932-940.
10	Akbari A, Abbasi S, Borumandnia N, et al. Epigenetic regulation of gastrointestinal cancers mediated by long non-coding RNAs[J]. Cancer Biomark, 2022, 35(4): 359-377.
11	Ma L, Gao J, Zhang N, et al. Long noncoding RNA SNHG17: a novel molecule in human cancers[J]. Cancer Cell Int. 2022, 22(1): 104-115.
12	Cao S, Li H, Li L. LncRNA SNHG17 contributes to the progression of cervical cancer by targeting microRNA-375-3p[J]. Cancer Manag Res, 2021, 13: 4969-4978.
13	Zhu XM, Li L, Ren LL, et al. LncRNA SNHG17 predicts poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2021, 25(12): 4219-4227.
14	Chen W, Wang L, Li X, et al. LncRNA SNHG17 regulates cell proliferation and invasion by targeting miR-338-3p/SOX4 axis in esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(9): 806-814.
15	Tang Z, Feng H, Shu L, et al. Identification of two novel lipid metabolism-related long non-coding RNAs (SNHG17 and LINC00837) as potential signatures for osteosarcoma prognosis and precise treatment[J]. BMC Med Genomics, 2023, 16(1): 115-127.
16	Kay FU, Kandathil A, Batra K, et al. Revisions to the Tumor, Node, Metastasis staging of lung cancer (8 edition): Rationale, radiologic findings and clinical implications[J]. World J Radiol, 2017, 9(6): 269-279.
17	Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future[J]. World J Clin Oncol, 2021, 12(4): 217-238.
18	Fois SS, Paliogiannis P, Zinellu A, et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer[J]. Int J Mol Sci, 2021, 22(2): 612-630.
19	García-Padilla C, Dueñas Á，García-López V, et al. Molecular mechanisms of lncRNAs in the dependent regulation of cancer and their potential therapeutic use[J]. Int J Mol Sci, 2022, 23(2): 764-784.
20	Luo Y, Lin J, Zhang J, et al. LncRNA SNHG17 contributes to proliferation, migration, and poor prognosis of hepatocellular carcinoma[J]. Can J Gastroenterol Hepatol, 2021, 2021(1): 9990338.
21	Ma T, Zhou X, Wei H, et al. Long non-coding RNA SNHG17 upregulates RFX1 by sponging miR-3180-3p and promotes cellular function in hepatocellular carcinoma[J]. Front Genet, 2021, 11: 607636.
22	Shen S, Liang J, Liang X, et al. SNHG17, as an EMT-related lncRNA, promotes the expression of c-Myc by binding to c-Jun in esophageal squamous cell carcinoma[J]. Cancer Sci, 2022, 113(1): 319-333.
23	Yang Z, Jiang Y, Wang L, et al. Prognosis and biological function of SGOL1 in clear cell renal cell carcinoma: a multiomics analysis[J]. BMC Med Genomics, 2024, 17(1): 60-80.
24	Wu J, Dong G, Liu T, et al. LncRNA SNHG17 promotes tumor progression and predicts poor survival in human renal cell carcinoma via sponging miR-328-3p[J]. Aging (Albany NY), 2021, 13(17): 21232-21250.
25	Zhang Z, Yan Y, Zhang B, et al. Long non-coding RNA SNHG17 promotes lung adenocarcinoma progression by targeting the microRNA-193a-5p/NETO2 axis[J]. Oncol Lett, 2021, 22(6): 818-829.
26	Zhang H, Wang SQ, Wang L, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression[J]. Cell Death Dis, 2022, 13(7): 657-669.
27	Bian Z, Zhou M, Cui K, et al. SNHG17 promotes colorectal tumorigenesis and metastasis via regulating Trim23-PES1 axis and miR-339-5p-FOSL2-SNHG17 positive feedback loop[J]. J Exp Clin Cancer Res, 2021, 40(1): 360-372.
28	Zhao H, Dong H, Wang P, et al. Long non-coding RNA SNHG17 enhances the aggressiveness of C4-2 human prostate cancer cells in association with β-catenin signaling[J]. Oncol Lett, 2021, 21(6): 472-481.

临床资料	低表达(n＝44)	高表达(n＝43)	χ²值	P值
既往吸烟	27(61.36)	34(79.07)	3.254	0.071
淋巴结转移	38(86.36)	37(86.05)	0.436	0.509
TNM分期			6.407	0.041
Ⅰ	15(34.09)	11(25.58)
Ⅱ	23(52.27)	16(37.21)
Ⅲ	6(13.64)	16(37.21)
EGFR突变	16(36.36)	11(25.58)	1.184	0.277
组织学亚型			0.987	0.610
腺癌	31(70.45)	26(60.47)
鳞癌	11(25.0)	14(32.56)
其他	2(4.55)	3(6.98)
辅助化疗	16(36.36)	13(30.23)	0.368	0.544
辅助放疗	28(63.64)	25(58.14)	0.276	0.599
WBC(×10⁹/L)			2.305	0.129
<10	42(95.45)	37(86.05)
≥10	2(4.55)	6(13.95)
NEU(×10⁹/L)			1.913	0.167
<7	41(93.18)	36(83.72)
≥7	3(6.82)	7(16.28)
LYM(×10⁹/L)			0.131	0.717
<4	40(90.91)	40(93.02)
≥4	4(9.09)	3(6.98)
PLT(×10⁹/L)			0.553	0.457
<300	28(63.64)	24(55.81)
≥300	16(36.36)	19(44.19)
EOS(×10⁹/L)			0.131	0.717
<0.50	40(90.91)	40(93.02)
≥0.50	4(9.09)	3(6.98)
BAS(×10⁹/L)			0.100	0.752
<0.10	39(88.64)	39(90.70)
≥0.10	5(11.36)	4(9.30)
CEA(ng/ml)			0.350	0.554
<5	27(61.36)	29(67.44)
≥5	17(38.64)	14(32.56)
NLR			2.212	0.137
<3	19(43.18)	12(27.91)
≥3	25(56.82)	31(72.09)

临床资料	低表达(n＝44)	高表达(n＝43)	χ²值	P值
既往吸烟	27(61.36)	34(79.07)	3.254	0.071
淋巴结转移	38(86.36)	37(86.05)	0.436	0.509
TNM分期			6.407	0.041
Ⅰ	15(34.09)	11(25.58)
Ⅱ	23(52.27)	16(37.21)
Ⅲ	6(13.64)	16(37.21)
EGFR突变	16(36.36)	11(25.58)	1.184	0.277
组织学亚型			0.987	0.610
腺癌	31(70.45)	26(60.47)
鳞癌	11(25.0)	14(32.56)
其他	2(4.55)	3(6.98)
辅助化疗	16(36.36)	13(30.23)	0.368	0.544
辅助放疗	28(63.64)	25(58.14)	0.276	0.599
WBC(×10⁹/L)			2.305	0.129
<10	42(95.45)	37(86.05)
≥10	2(4.55)	6(13.95)
NEU(×10⁹/L)			1.913	0.167
<7	41(93.18)	36(83.72)
≥7	3(6.82)	7(16.28)
LYM(×10⁹/L)			0.131	0.717
<4	40(90.91)	40(93.02)
≥4	4(9.09)	3(6.98)
PLT(×10⁹/L)			0.553	0.457
<300	28(63.64)	24(55.81)
≥300	16(36.36)	19(44.19)
EOS(×10⁹/L)			0.131	0.717
<0.50	40(90.91)	40(93.02)
≥0.50	4(9.09)	3(6.98)
BAS(×10⁹/L)			0.100	0.752
<0.10	39(88.64)	39(90.70)
≥0.10	5(11.36)	4(9.30)
CEA(ng/ml)			0.350	0.554
<5	27(61.36)	29(67.44)
≥5	17(38.64)	14(32.56)
NLR			2.212	0.137
<3	19(43.18)	12(27.91)
≥3	25(56.82)	31(72.09)

影响因素	单因素分析			多因素分析
影响因素	HR	95%CI	P值	HR	95%CI	P值
吸烟史	2.095	1.038～4.226	0.039	1.191	0.562～2.526	0.648
淋巴结转移	1.581	0.933～2.679	0.089	－	－	－
TNM分期≥Ⅲ	1.878	1.012～3.483	0.046	1.467	0.781～2.753	0.233
EGFR突变	0.683	0.346～1.345	0.270	－	－	－
病理亚型-腺癌	0.948	0.723～1.242	0.699	－	－	－
辅助化疗	0.584	0.297～1.151	0.120	－	－	－
辅助放疗	0.538	0.300～0.965	0.038	0.669	0.370～1.210	0.183
WBC≥10×10⁹/L	1.292	0.833～2.002	0.252	－	－	－
NEU≥7×10⁹/L	1.083	0.920～1.276	0.339	－	－	－
LYM≥4×10⁹/L	0.652	0.377～1.127	0.126	－	－	－
PLT≥300×10⁹/L	1.001	0.998～1.004	0.506	－	－	－
EOS≥0.50×10⁹/L	1.178	0.421～3.292	0.755	－	－	－
BAS≥0.10×10⁹/L	0.723	0.224～2.332	0.587	－	－	－
CEA≥5 ng/ml	1.624	0.905～2.912	0.104	－	－	－
NLR≥3	1.484	0.830～2.654	0.183	－	－	－
SNHG17高表达	4.218	2.136～8.329	0.001	3.533	1.687～7.399	0.001

影响因素	单因素分析			多因素分析
影响因素	HR	95%CI	P值	HR	95%CI	P值
吸烟史	2.095	1.038～4.226	0.039	1.191	0.562～2.526	0.648
淋巴结转移	1.581	0.933～2.679	0.089	－	－	－
TNM分期≥Ⅲ	1.878	1.012～3.483	0.046	1.467	0.781～2.753	0.233
EGFR突变	0.683	0.346～1.345	0.270	－	－	－
病理亚型-腺癌	0.948	0.723～1.242	0.699	－	－	－
辅助化疗	0.584	0.297～1.151	0.120	－	－	－
辅助放疗	0.538	0.300～0.965	0.038	0.669	0.370～1.210	0.183
WBC≥10×10⁹/L	1.292	0.833～2.002	0.252	－	－	－
NEU≥7×10⁹/L	1.083	0.920～1.276	0.339	－	－	－
LYM≥4×10⁹/L	0.652	0.377～1.127	0.126	－	－	－
PLT≥300×10⁹/L	1.001	0.998～1.004	0.506	－	－	－
EOS≥0.50×10⁹/L	1.178	0.421～3.292	0.755	－	－	－
BAS≥0.10×10⁹/L	0.723	0.224～2.332	0.587	－	－	－
CEA≥5 ng/ml	1.624	0.905～2.912	0.104	－	－	－
NLR≥3	1.484	0.830～2.654	0.183	－	－	－
SNHG17高表达	4.218	2.136～8.329	0.001	3.533	1.687～7.399	0.001

[1]	Zhongzheng Ma, Yunchuan Yang, Xiang Ma, Chi Zhou, Ding Ding, Junyi Huo, Nan Xu, Peiyuan Cui, Lei Zhou. Construction of a disulfidptosis-related lncRNA prognostic model for pancreatic cancer and study of immune response [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 368-376.
[2]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[3]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[4]	Xiangyu Qu, Yigang Zhang, Haoling Li, Tian Qiu, Yi Tan. Diagnostic and prognostic role of USP24 and its co-expression of tumor metabolic genes in hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 659-662.
[5]	Wen Gu, Shouxin Ling, Haili Tang, Xuemei Gan. Comparison of two different surgical approaches for open radical surgery in patients with papillary thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 687-690.
[6]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[7]	Jianna Sun, Lingjun Kong, Chongxi Ren, Kun Mu, Xiaorui Wang. Prognostic analysis of 266 patients with stage IV breast cancer undergoing surgery for the first time [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 502-505.
[8]	Qinggang Yuan, Lixiang Liu, Liang Zhang, Shizhen Zhou, Bo Gao, Chao Ding, Wenxian Guan. Urea-creatinine ratio (UCR) predicts the long-term prognosis of colorectal cancer patients after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 506-509.
[9]	Fu Huang, Qian Wang, Xiangren Jin, Yunchuan Tang. Study on the relationship between the expression of VEGFR2 and miR-27a-5p in gastric cancer tissues and clinicopathological parameters and prognosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 558-561.
[10]	Yu Zhang, Mengni Jiang. Establishment of prediction model for survival benefits of locally advanced pancreatic cancer patients after radiochemotherapy based on DWI signal value [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 657-664.
[11]	Xirong Wu, Liwen Xu, Yaqiong Chen. Prognosis model for patients with liver failure based on LPR and FARI [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 675-681.
[12]	Jun Liu, Wenjing Qiu, Fanghao Sun, Songying Li, Shuhong Yi, Binsheng Fu, Yang Yang, Hui Luo. Comparison of in vivo and in vitro split liver transplantation in pediatric liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 688-693.
[13]	Dan Xiao, Chen Chen, Yejun Zha, Maoqi Gong, Kehan Hua, Weitong Sun, Xieyuan Jiang. Clinical prognosis and risk factors of post-traumatic elbow stiffness treated by modified elbow arthrolysis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(05): 257-263.
[14]	Shi Tang, Chuanyou Xue, Xing Ye, Hongju Zhang, Rui Dai. Changes of blood lipid, blood glucose, protein and uric acid in patients with acute viral hepatitis and their correlation with prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 396-399.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export